Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 2.41B |
| Revenue (ttm) | 673.00M |
| Net Income (ttm) | -575.00M |
| Shares Out | 98.12M |
| EPS (ttm) | -5.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,725,212 |
| Open | 24.32 |
| Previous Close | 23.99 |
| Day's Range | 24.25 - 25.14 |
| 52-Week Range | 18.29 - 42.37 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 59.95 (+144.4%) |
| Earnings Date | May 4, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $59.95, which is an increase of 144.40% from the latest price.
News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra...
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026
PHILADELPHIA, April 3, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ...
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 Program to be externall...
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares are down on Thursday as the company reported data from its Phase 3 study of DTX301, a gene therapy for ornithine transcarbamylase (OTC) deficiency.
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
Ultragenyx Pharmaceutical said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder.
Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Strong commercial growth supports a robust pipeline, with pivotal Angelman and gene therapy programs advancing toward key regulatory milestones. Angelman Phase 3 design addresses placebo effect, and gene therapy durability is supported by long-term data. GSDIa and Sanfilippo approvals are expected in the second half of the year.
Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a diverse rare disease pipeline, with near-term regulatory decisions expected for GSD1A and Sanfilippo, and a pivotal Angelman phase III data readout anticipated in the second half of the year. Profitability is targeted for 2027, supported by a broad commercial footprint and robust late-stage programs.
Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
Key updates include strong progress in Angelman syndrome trials, with Aspire phase III powered for cognition and MDRI endpoints, and Aurora supporting broader labeling. Setrusumab shows promise for bone disease with accelerated approval in view. Gene therapy programs advance despite regulatory delays, with launches for Sanfilippo and GSDIa prioritized.
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic...
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmace...
Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc...
Why Is Ultragenyx Stock Sinking Friday?
“The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commercial...
Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025
Delivered 20% revenue growth in 2025, surpassing guidance, with strong commercial execution and expansion across four products. Strategic restructuring aims for profitability by 2027, supported by cost reductions, new launches, and PRV monetization. Regulatory and market risks remain.
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
2025 total revenue of $673 million, Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui...
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit
NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc...
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel...
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be pres...
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III ...
Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company highlighted robust growth in rare disease treatments, with four commercial products and a strong pipeline including gene therapies for Sanfilippo, glycogen storage disease, and Angelman syndrome. Setrusumab showed BMD and pain improvements but missed fracture endpoints, prompting further analysis.
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 c...
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc. (“Ultragenyx" or the "Company") (NASDAQ: RARE) investors that the firm has initiated an inve...